financetom
Business
financetom
/
Business
/
Exclusive-Boeing, Airbus to share Taiwan's China Airlines passenger jet order, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive-Boeing, Airbus to share Taiwan's China Airlines passenger jet order, sources say
Nov 9, 2024 11:50 AM

TAIPEI/PARIS (Reuters) - Taiwan's China Airlines is nearing a decision to split a multi-billion-dollar order for long-distance passenger jets between Airbus and Boeing ( BA ), while an order for freighters hangs in the balance, industry sources told Reuters.

The decision will come as the United States' presidential election ended with the Republican Donald Trump sweeping back into office, and Taiwan keen to ensure the new U.S. government understands Taipei's desire to ensure strong relations continue.

Taiwan's largest carrier has been weighing Boeing's ( BA ) 777X and the Airbus A350-1000 as replacements for its fleet of 10 Boeing 777-300ERs and to provide capacity for future growth.

The sources said China Airlines could order as many as 20 passenger jets to be split equally between the two plane giants, while the choice of freighters was at least partly being weighed against the backdrop of U.S. presidential elections.

Such a deal for the passenger jets would be worth almost $4 billion after typical industry discounts, according to estimated delivery prices from aviation consultancy Cirium Ascend.

A final decision depends on the airline's board, the sources said.

China Airlines told Reuters that it plans its fleet "based on market demand and corporate developments, and carefully studies the relevant technical and commercial conditions to select the most appropriate aircraft type".

Airbus and Boeing ( BA ) declined comment.

Multibillion-dollar deals for new aircraft often have to take political as well as business considerations into account - especially in the case of Taiwan, given its international situation and pressure it faces to give in to China's sovereignty claims, which are rejected by the democratically elected government in Taipei.

The U.S. is Taiwan's most important international backer and arms supplier despite a lack of formal diplomatic ties, and China Airlines' majority owner is the Taiwan government.

Trump's first administration strongly supported Taiwan, but comments he made on the campaign trail saying the island needed to pay for Washington's protection and that Taiwan stole U.S. semiconductor business unnerved Taipei.

Taiwan's government swiftly congratulated Trump on his election win and says it is confident of strong ties.

Industry sources say Taiwan has traditionally been seen as one of several key markets where the diplomatic context can help to sway a purchase decision one way or another, on top of the stringent technical evaluations carried out by airlines.

Last month, however, the airline's chairman denied it was facing any political pressure over its fleet decisions.

Hsieh Shih-chien told reporters that only China Airlines itself made the assessments about which aircraft to buy.

(Reporting by Ben Blanchard and Tim Hepher; Editing by Lincoln Feast.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
Jun 5, 2024
05:04 PM EDT, 06/05/2024 (MT Newswires) -- Relay Therapeutics ( RLAY ) unveiled late Wednesday a clinical trial collaboration with Pfizer ( PFE ) to evaluate a treatment for patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. The partnership is evaluating atirmociclib, Pfizer's ( PFE ) investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant, Relay Therapeutics ( RLAY )...
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results
Jun 5, 2024
05:04 PM EDT, 06/05/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Wednesday that VTX3232 effectively reduced body weight and food intake during two preclinical diet-induced obesity mouse model studies. The results show that the drug decreased liver steatosis and triglycerides, and also had greater benefits in combination with semaglutide, according to the company. The company said it plans...
Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing
Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing
Jun 5, 2024
05:05 PM EDT, 06/05/2024 (MT Newswires) -- Marc N Casper, Director, Chairman & CEO, on June 03, 2024, sold 20,000 shares in Thermo Fisher Scientific ( TMO ) for $11,374,358. Following the Form 4 filing with the SEC, Casper has control over a total of 183,724 shares of the company, with 123,816 shares held directly and 59,908 controlled indirectly. SEC...
Kyndryl Holdings Insider Sold Shares Worth $802,244, According to a Recent SEC Filing
Kyndryl Holdings Insider Sold Shares Worth $802,244, According to a Recent SEC Filing
Jun 5, 2024
05:04 PM EDT, 06/05/2024 (MT Newswires) -- Vineet Khurana, Senior Vice President & Global Controller, on June 03, 2024, sold 30,430 shares in Kyndryl Holdings ( KD ) for $802,244. Following the Form 4 filing with the SEC, Khurana has control over a total of 78,722 shares of the company, with 78,722 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1867072/000112760224017950/xslF345X03/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved